Buying leakage is one of those issues that tends to settle quietly into the background of pharmacy operations. When I speak to pharmacy owners and managers, most feel that buying is broadly under control because orders are placed on time, invoices are paid and patients are not being turned away.
From the outside in, that creates a sense that things are working as they should.
The difficulty is that pharmacy buying leakage rarely announces itself through obvious failures - it shows up gradually. In my experience, leakage isn’t the result of poor practice. It is the result of small, reasonable decisions being made repeatedly in an environment that does not always make those decisions easy to see together.
In real terms, buying leakage usually starts with pressure.
A delivery does not arrive when expected, so the item is ordered again from a different supplier to avoid delaying patients. An invoice looks close enough to expectations to be approved without detailed checking because there is little time to question it. Stock levels increase slowly because holding extra feels safer than risking a shortage, particularly when staffing is stretched or demand is unpredictable.
Each of these actions makes sense in isolation.
The problem is that pharmacies rarely have the opportunity to view them alongside one another. Over time, duplication becomes embedded, excess stock becomes normal, and cash becomes tied up in products that are not moving in line with dispensing activity. Because none of this happens suddenly, it is easy for it to persist without being challenged.
Many pharmacies rely on cascade or buying reports to reassure themselves that procurement is working as intended. These reports are valuable, but they are often mistaken for evidence of control rather than a partial view of activity.
They show what was ordered, but they do not confirm whether that order arrived in full, whether it matched the invoice or whether it was ultimately dispensed.
When those elements are not reviewed together, pharmacies can feel confident about buying while margin quietly erodes. In my experience, control comes from visibility rather than compliance - knowing that ordering routes are followed is useful, but knowing that ordering, invoicing and dispensing align consistently is what actually protects margin.
High‑value medicines tend to expose buying leakage more quickly than anything else.
Weight‑management medicines are a good example because the dispensing margin is minimal and availability can be inconsistent. In that context, even small discrepancies between what was ordered, what was paid for and what was dispensed have an immediate financial impact.
I have seen pharmacies assume that margin pressure in these areas is simply unavoidable, when in reality a lack of visibility is intensifying the problem. Without joined‑up data, it becomes difficult to distinguish between genuine external pressure and loss created by internal blind spots.
When we work with pharmacies, I do not encourage them to introduce additional rules or layers of administration. Most teams are already operating under significant pressure! What I do encourage is a change in where attention is directed.
Pharmacies that manage buying effectively tend to notice patterns rather than isolated incidents. They become curious when emergency reorders stop being occasional, they question rising spend when dispensing activity does not reflect the same increase, and they look more closely at stock levels that feel comfortable rather than purposeful.
Most importantly, reconciliation becomes part of ongoing visibility rather than something reserved for moments of concern. Regularly comparing what was ordered with what was invoiced and what was dispensed allows issues to surface early, while there is still room to adjust behaviour rather than absorb loss.
This is where pharmacy business intelligence becomes genuinely useful.
Ordering data, invoice data, dispensing data and stock information each tells a limited story on its own. When they are viewed together, context appears, and assumptions can be tested.
At RWA Pharmacy, we consistently see that once pharmacies gain this joined‑up view of their data, buying decisions become more deliberate. Stock levels are held with clearer intent. Margin pressure becomes easier to understand and explain, rather than something that appears unexpectedly at the end of the month.
Buying leakage is rarely dramatic, but in an environment where pharmacy margins are already under strain, reducing it can have a meaningful impact. For me, the aim has never been perfection - it has always been clarity, because clarity allows pharmacies to protect cash, buy with confidence and focus their time where it delivers the most value.
I explored this topic in more detail during my recent appearance on the Pharmacy Planet podcast, where we discussed buying leakage, reconciliation and the importance of visibility across ordering, invoicing and dispensing.
You can watch the full episode here.
If you want clearer insight into buying behaviour, margins and stock performance, RWA Pharmacy’s platform brings pharmacy data together in one place, helping identify leakage, reduce duplication and support more confident buying decisions.
Interested to learn more?
Interested to learn more?
Sign up and stay up to date
Interested to learn more about RWA Pharmacy, our solutions and innovations? Sign up to our email newsletter here!
